- Home
- AFYA vs DNLI Comparison
AFYA vs DNLI Comparison
Compare AFYA & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFYA
- DNLI
- Stock Information
- Founded
- AFYA 1999
- DNLI 2013
- Country
- AFYA Brazil
- DNLI United States
- Employees
- AFYA N/A
- DNLI N/A
- Industry
- AFYA Other Consumer Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AFYA Real Estate
- DNLI Health Care
- Exchange
- AFYA Nasdaq
- DNLI Nasdaq
- Market Cap
- AFYA 1.6B
- DNLI 1.8B
- IPO Year
- AFYA 2019
- DNLI 2017
- Fundamental
- Price
- AFYA $18.20
- DNLI $12.74
- Analyst Decision
- AFYA Sell
- DNLI Strong Buy
- Analyst Count
- AFYA 5
- DNLI 16
- Target Price
- AFYA $17.60
- DNLI $37.57
- AVG Volume (30 Days)
- AFYA 85.4K
- DNLI 1.7M
- Earning Date
- AFYA 05-08-2025
- DNLI 05-06-2025
- Dividend Yield
- AFYA 1.28%
- DNLI N/A
- EPS Growth
- AFYA 62.30
- DNLI N/A
- EPS
- AFYA 1.12
- DNLI N/A
- Revenue
- AFYA $534,257,467.00
- DNLI N/A
- Revenue This Year
- AFYA $15.00
- DNLI N/A
- Revenue Next Year
- AFYA $9.11
- DNLI $372.05
- P/E Ratio
- AFYA $16.24
- DNLI N/A
- Revenue Growth
- AFYA 14.90
- DNLI N/A
- 52 Week Low
- AFYA $14.52
- DNLI $10.57
- 52 Week High
- AFYA $20.06
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- AFYA 58.30
- DNLI 42.15
- Support Level
- AFYA $17.62
- DNLI $12.37
- Resistance Level
- AFYA $18.28
- DNLI $13.63
- Average True Range (ATR)
- AFYA 0.62
- DNLI 1.24
- MACD
- AFYA 0.02
- DNLI 0.23
- Stochastic Oscillator
- AFYA 89.80
- DNLI 50.94
About AFYA Afya Limited
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medicine, other health sciences, and other undergraduate programs, Continuing Education provides specialization programs and graduate courses in medicine; and Digital Services provides content and technology for medical education, clinical decisions software, practice management tools (that encompass electronic medical records, telemedicine, and digital prescription, and provides access, demand and efficiency for the healthcare players.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.